Haleos Labs Limited
Incorporated in 2006, SMS Lifesciences Ltd is in the business of manufacturing of Active Pharma Ingredients and their intermediates[1]
- Market Cap ₹ 419 Cr.
- Current Price ₹ 1,387
- High / Low ₹ 1,680 / 956
- Stock P/E 22.0
- Book Value ₹ 684
- Dividend Yield 0.11 %
- ROCE 13.9 %
- ROE 11.4 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- The company has delivered a poor sales growth of 5.35% over past five years.
- Company has a low return on equity of 8.90% over last 3 years.
- Dividend payout has been low at 3.00% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 218 | 213 | 344 | 257 | 260 | 346 | 315 | 300 | 333 | 325 | |
| 0 | 0 | 0 | 189 | 200 | 312 | 233 | 230 | 314 | 289 | 265 | 289 | 285 | |
| Operating Profit | 0 | 0 | 0 | 28 | 13 | 33 | 24 | 30 | 31 | 26 | 35 | 44 | 40 |
| OPM % | 13% | 6% | 9% | 9% | 11% | 9% | 8% | 12% | 13% | 12% | |||
| 0 | 0 | 0 | 2 | 3 | 2 | 2 | 1 | 14 | 5 | 4 | 4 | 4 | |
| Interest | 0 | 0 | 0 | 6 | 4 | 5 | 5 | 5 | 5 | 5 | 9 | 8 | 7 |
| Depreciation | 0 | 0 | 0 | 6 | 6 | 6 | 7 | 7 | 8 | 8 | 10 | 10 | 10 |
| Profit before tax | 0 | 0 | 0 | 18 | 6 | 24 | 13 | 19 | 33 | 18 | 19 | 30 | 26 |
| Tax % | 30% | -2% | 30% | 31% | 32% | 23% | 28% | 32% | 29% | ||||
| 0 | 0 | 0 | 13 | 6 | 17 | 9 | 13 | 25 | 13 | 13 | 21 | 19 | |
| EPS in Rs | 21.50 | 55.01 | 30.26 | 43.56 | 83.95 | 43.73 | 43.23 | 70.68 | 63.01 | ||||
| Dividend Payout % | 0% | 0% | 3% | 0% | 3% | 2% | 3% | 3% | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | -1% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 10% |
| TTM: | -12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 28% |
| 1 Year: | 16% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | 9% |
| Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 0.01 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 0 | -0 | -0 | 82 | 85 | 102 | 110 | 123 | 148 | 161 | 173 | 194 | 204 |
| 0 | 0 | 0 | 26 | 27 | 47 | 50 | 45 | 62 | 87 | 92 | 82 | 67 | |
| 0 | 0 | 0 | 67 | 61 | 98 | 66 | 101 | 99 | 86 | 80 | 80 | 78 | |
| Total Liabilities | 0 | 0 | 0 | 175 | 177 | 251 | 229 | 272 | 312 | 337 | 348 | 358 | 352 |
| 0 | 0 | 0 | 73 | 69 | 88 | 94 | 101 | 99 | 140 | 138 | 150 | 146 | |
| CWIP | 0 | 0 | 0 | 0 | 7 | 1 | 2 | 3 | 21 | 1 | 6 | 0 | 8 |
| Investments | 0 | 0 | 0 | 0 | 5 | 26 | 26 | 26 | 23 | 23 | 23 | 23 | 23 |
| 0 | 0 | 0 | 102 | 95 | 135 | 106 | 142 | 169 | 174 | 181 | 184 | 174 | |
| Total Assets | 0 | 0 | 0 | 175 | 177 | 251 | 229 | 272 | 312 | 337 | 348 | 358 | 352 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 20 | 8 | 27 | 14 | 22 | -15 | 5 | 15 | 28 | |
| 0 | 0 | 0 | -8 | -7 | -43 | -13 | -6 | -7 | -28 | -14 | -14 | |
| 0 | 0 | 0 | -12 | -1 | 18 | -2 | -8 | 15 | 23 | -1 | -14 | |
| Net Cash Flow | 0 | 0 | 0 | -0 | 0 | 2 | -1 | 8 | -8 | -1 | 0 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 65 | 46 | 39 | 31 | 42 | 36 | 53 | 60 | 71 | |||
| Inventory Days | 133 | 135 | 117 | 138 | 154 | 143 | 154 | 168 | 131 | |||
| Days Payable | 168 | 122 | 133 | 91 | 147 | 124 | 105 | 111 | 99 | |||
| Cash Conversion Cycle | 30 | 60 | 23 | 78 | 48 | 54 | 102 | 116 | 102 | |||
| Working Capital Days | 43 | 41 | 20 | 27 | 31 | 44 | 65 | 61 | 57 | |||
| ROCE % | 0% | 0% | 46% | 9% | 22% | 12% | 14% | 13% | 9% | 11% | 14% |
Documents
Announcements
-
Report (Special Window)
8 Dec - Special window July 7, 2025–Jan 6, 2026; November re-lodgement requests: NIL.
-
Demand Notice
6 Dec - Received Rs87,58,901 demand notice for Apr 2015–Jun 2016; company to pursue legal remedies.
-
New Logo
25 Nov - Board approved new company logo on November 25, 2025 following name change.
-
New Scrip ID (HALEOSLABS)
25 Nov - Rename to Haleos Labs Limited; symbol changed to HALEOSLABS effective November 26, 2025.
- Newspaper Publication (Financial Results) 12 Nov
Annual reports
Concalls
-
Jul 2025TranscriptAI SummaryPPT
Business Overview:[1][2][3]
The company is the demerged entity of SMS Pharmaceuticals Ltd. It has a diversified product portfolio focused on the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates, with offerings spanning several therapeutic segments, including gastro-intestinal, anti-ulcer, anti-hypertensive, erectile dysfunction, anti-convulsant, anti-infective, and more